Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, India.
Inflammopharmacology. 2021 Aug;29(4):1061-1074. doi: 10.1007/s10787-021-00837-4. Epub 2021 Jun 29.
The liver acts as a manufacturing unit for the production of fetuin-A, which is essential for various physiological characteristics. Scientific research has shown that a moderate upward push in fetuin-A serum levels is associated with a confirmed non-alcoholic fatty liver disease (NAFLD) diagnosis. Fetuin-A modulation is associated with a number of pathophysiological variables that cause liver problems, including insulin receptor signaling deficiencies, adipocyte dysfunction, hepatic inflammation, fibrosis, triacylglycerol production, macrophage invasion, and TLR4 activation. The focus of the present review is on the various molecular pathways, and genetic relevance of mRNA expression of fetuin-A which is correlated with progression of NAFLD. The other major area of exploration in the present review is based on the new targets for the modulation of fetuin-A, like calorie restriction and novel pharmacological agents, such as rosuvastatin, metformin, and pioglitazone which are successfully implicated in the management of various liver-related complications.
肝脏作为胎球蛋白 A 的生产制造单位,对于各种生理特征都至关重要。科学研究表明,胎球蛋白 A 血清水平适度上升与已确诊的非酒精性脂肪性肝病 (NAFLD) 诊断相关。胎球蛋白 A 的调节与许多引起肝脏问题的病理生理变量相关,包括胰岛素受体信号转导缺陷、脂肪细胞功能障碍、肝炎症、纤维化、三酰甘油生成、巨噬细胞浸润和 TLR4 激活。本综述的重点是胎球蛋白 A 的各种分子途径和 mRNA 表达的遗传相关性,这与 NAFLD 的进展相关。本综述的另一个主要探索领域是基于胎球蛋白 A 调节的新靶点,如热量限制和新型药理学制剂,如瑞舒伐他汀、二甲双胍和吡格列酮,它们成功地被用于各种与肝脏相关的并发症的治疗。